/PRNewswire/ Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the.
GERMANTOWN, Md., March 28, 2023 /PRNewswire/ Precigen, Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of. | March 28, 2023
– Achieved significant clinical progress for UltraCAR-T® and AdenoVerse™ investigational therapeutics in 2022 – – Presented positive clinical data for.
/PRNewswire/ Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Precigen.
/PRNewswire/ Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a.